Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.

Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD; SABER Collaboration..

Arthritis Rheum. 2013 Jan;65(1):48-58. doi: 10.1002/art.37740.

2.

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR.

JAMA. 2011 Dec 7;306(21):2331-9. doi: 10.1001/jama.2011.1692. Epub 2011 Nov 6.

3.

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.

Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR.

JAMA. 2013 Mar 6;309(9):887-95. doi: 10.1001/jama.2013.1099.

4.

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium.; BSRBR..

Ann Rheum Dis. 2009 Feb;68(2):209-15. doi: 10.1136/ard.2007.087288. Epub 2008 Apr 2.

5.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

6.

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.

Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR.

Ann Rheum Dis. 2014 Nov;73(11):1942-8. doi: 10.1136/annrheumdis-2013-203407. Epub 2013 Jul 13.

7.

Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?

Toh S, Li L, Harrold LR, Bayliss EA, Curtis JR, Liu L, Chen L, Grijalva CG, Herrinton LJ.

Pharmacoepidemiol Drug Saf. 2012 May;21(5):524-34. doi: 10.1002/pds.3238. Epub 2012 Mar 13.

8.

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.

Maneiro JR, Salgado E, Gomez-Reino JJ.

JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430. Review.

PMID:
23797343
9.

Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.

Arthritis Rheum. 2008 Mar;58(3):667-77. doi: 10.1002/art.23281.

10.

Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases.

Kawai VK, Grijalva CG, Arbogast PG, Curtis JR, Solomon DH, Delzell E, Chen L, Ouellet-Hellstrom R, Herrinton L, Liu L, Mitchell EF Jr, Stein CM, Griffin MR.

Arthritis Care Res (Hoboken). 2013 Jul;65(7):1085-94. doi: 10.1002/acr.21937.

11.

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.

Raaschou P, Simard JF, Holmqvist M, Askling J; ARTIS Study Group..

BMJ. 2013 Apr 8;346:f1939. doi: 10.1136/bmj.f1939.

12.

Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.

Asgari MM, Ray GT, Geier JL, Quesenberry CP.

J Am Acad Dermatol. 2017 Apr;76(4):632-638. doi: 10.1016/j.jaad.2016.10.006. Epub 2017 Feb 3.

PMID:
28162854
13.

Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.

Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Lewis JD, Ouellet-Hellstrom R, Patkar NM, Saag KG, Winthrop KL, Curtis JR; SABER Collaboration..

Arthritis Rheum. 2012 Aug;64(8):2773-80. doi: 10.1002/art.34458.

14.

Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.

Accortt NA, Bonafede MM, Collier DH, Iles J, Curtis JR.

Arthritis Rheumatol. 2016 Jan;68(1):67-76. doi: 10.1002/art.39416.

15.

Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.

Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE.

Am J Gastroenterol. 2011 Dec;106(12):2146-53. doi: 10.1038/ajg.2011.283. Epub 2011 Oct 25.

PMID:
22031357
16.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.

PMID:
23032984
17.

Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.

Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH.

Arthritis Rheum. 2007 Jun;56(6):1754-64.

18.

The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.

Ljung L, Askling J, Rantapää-Dahlqvist S, Jacobsson L; ARTIS Study Group..

Arthritis Res Ther. 2014 Jun 18;16(3):R127. doi: 10.1186/ar4584.

19.

Treatment with biologic therapies and the risk of cancer in patients with IBD.

Biancone L, Calabrese E, Petruzziello C, Pallone F.

Nat Clin Pract Gastroenterol Hepatol. 2007 Feb;4(2):78-91. Review.

PMID:
17268543
20.

Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy.

Cooper WO, Cheetham TC, Li DK, Stein CM, Callahan ST, Morgan TM, Shintani AK, Chen N, Griffin MR, Ray WA.

Arthritis Rheumatol. 2014 Feb;66(2):444-50. doi: 10.1002/art.38262.

Supplemental Content

Support Center